03.03.2013 Views

Supplementum 163 - Swiss Medical Weekly

Supplementum 163 - Swiss Medical Weekly

Supplementum 163 - Swiss Medical Weekly

SHOW MORE
SHOW LESS

Create successful ePaper yourself

Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.

39 S SWISS MED WKLY 2008;138(Suppl <strong>163</strong>) · www.smw.ch<br />

Poster Viewing<br />

were recruited in the Out-patient Clinic for Allergology, University of<br />

Bern. Atopy patch tests (APT) were performed with biologically<br />

standardized (200 IR/g) cockroach and house-dust mite extracts<br />

(Stallergènes, France) and evaluated after 48 and 72 hours. In<br />

addition, skin prick tests (SPT) with a panel of common inhalant<br />

allergens, total serum IgE, and specific IgE tests for cockroach and<br />

house dust mites were performed.<br />

Resultats: A positive APT reaction to cockroach was found in 10/23<br />

(43%) patients with AD, a positive SPT in 6/23 (26%) patients. Twelve<br />

of the 23 (52%) patients with AD were also sensitized to house-dust<br />

mites. Positive APT reactions for cockroach showed no significant<br />

correlation with the SPT and specific IgE levels for this allergen. There<br />

was no significant correlation between the positive SPT, APT and<br />

specific IgE to cockroach and house dust mite. No positive test<br />

reactions were observed in the non-atopic controls.<br />

Conclusion: Our results suggest that cockroach allergens can trigger<br />

eczematous skin test reactions in a substantial number of patients<br />

with AD. There was no significant relationship between cockroach<br />

and house-dust mite sensitivity detected.<br />

P172<br />

Dextran sulfate attenuates cold ischaemia-induced innate<br />

immune response and facilitates RIB 5/2-induced long-term<br />

allograft survival<br />

T. Gajanayake1 , B. Sawitzki2 , K. Matozan1 , E. Korchagina3 ,<br />

M. Lehmann4 , H.D. Volk2 , R. Rieben1 .<br />

1 University of Berne (Berne, CH); 2 University of Medicine Berlin<br />

(Berlin, D); 3 Russian Academy<br />

of Sciences (Moscow, RUS); 4 University of Rostock (Rostock, D)<br />

Ischemia/reperfusion (I/R) injury of a graft leads to an increased<br />

activation of the innate immune response of the recipient. This boost<br />

of anti-graft immune response may be the reason for failure of<br />

immunological tolerance induction in the context of prolonged graft<br />

ischemia times. Here we show that treatment with the endothelial cell<br />

(EC) protectant dextran sulfate (DXS, MW 5000) restores a quiescent<br />

and ‘non-dangerous’ state of the graft and facilitates long-term<br />

survival.<br />

Heterotopic heart transplantation from DA to Lewis rats was carried<br />

out and long-term graft survival induced by non-depleting anti-CD4<br />

monoclonal antibody (RIB 5/2) with or without DXS. Cold graft<br />

ischemia was either 20 min or 12 h. Median survival times (MST) of<br />

RIB 5/2 only or RIB 5/2+DXS treated recipients in the 20 min ischemia<br />

group were 86 and 81 days, respectively, with >30% of long-term<br />

graft survival (>175 d) in both groups. In the 12 h ischemia group RIB<br />

5/2 only treatment led to chronic rejection (MST = 49.5 d). In contrast,<br />

treatment with RIB 5/2+DXS induced long-term graft survival (MST =<br />

100d, p

Hooray! Your file is uploaded and ready to be published.

Saved successfully!

Ooh no, something went wrong!